Abstract #5427

MR-HIFU mild hyperthermia for recurrent rectal cancer: updated results from a phase I clinical trial

William Chu¹, Robert M Staruch², Samuel Pichardo^3,4, Yuexi Huang⁵, Merrylee McGuffin¹, Ruby Endre⁵, Gregory Czarnota⁶, and Kullervo Hynynen⁵

¹Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ²Clinical Sites Research Program, Philips Research, Cambridge, MA, United States, ³Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada, ⁴Electrical Engineering, Lakehead University, Thunder Bay, ON, Canada, ⁵Physical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada, ⁶Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

We present the updated results of our phase I trial that delivers mild hyperthermia using magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) combined with radiation and chemotherapy in the treatment of locally recurrent rectal cancer. Participation in the study is based on careful consideration of patient and tumor factors. MR-HIFU mild hyperthermia was delivered in three sessions during a 17-day regimen. MR-HIFU mild hyperthermia was successfully delivered and the procedure was well tolerated. No adverse effects have been reported following the combined treatment to date.

This abstract and the presentation materials are available to members only; a login is required.

Join Here